🇺🇸 Measles-Mumps-Rubella in United States
226 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 226
Most-reported reactions
- Pyrexia — 52 reports (23.01%)
- Contraindicated Product Administered — 30 reports (13.27%)
- Rash — 24 reports (10.62%)
- Measles — 23 reports (10.18%)
- Cough — 20 reports (8.85%)
- Decreased Appetite — 16 reports (7.08%)
- Drug Ineffective — 16 reports (7.08%)
- Depression — 15 reports (6.64%)
- Diarrhoea — 15 reports (6.64%)
- Drug Intolerance — 15 reports (6.64%)
Other Immunology / Infectious Disease approved in United States
Frequently asked questions
Is Measles-Mumps-Rubella approved in United States?
Measles-Mumps-Rubella does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Measles-Mumps-Rubella in United States?
Hospital Clinic of Barcelona is the originator. The local marketing authorisation holder may differ — check the official source linked above.